JPH0586376B2 - - Google Patents

Info

Publication number
JPH0586376B2
JPH0586376B2 JP59504070A JP50407084A JPH0586376B2 JP H0586376 B2 JPH0586376 B2 JP H0586376B2 JP 59504070 A JP59504070 A JP 59504070A JP 50407084 A JP50407084 A JP 50407084A JP H0586376 B2 JPH0586376 B2 JP H0586376B2
Authority
JP
Japan
Prior art keywords
cldc
deoxycytidine
tumor
hours
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59504070A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61500224A (ja
Inventor
Sherudan Bii Guriiru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS61500224A publication Critical patent/JPS61500224A/ja
Publication of JPH0586376B2 publication Critical patent/JPH0586376B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP59504070A 1983-10-26 1984-10-26 腫瘍性組織を放射線に対して増感する医薬組成物 Granted JPS61500224A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54569383A 1983-10-26 1983-10-26
US545693 1983-10-26

Publications (2)

Publication Number Publication Date
JPS61500224A JPS61500224A (ja) 1986-02-06
JPH0586376B2 true JPH0586376B2 (enExample) 1993-12-10

Family

ID=24177186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59504070A Granted JPS61500224A (ja) 1983-10-26 1984-10-26 腫瘍性組織を放射線に対して増感する医薬組成物

Country Status (5)

Country Link
EP (1) EP0160079B1 (enExample)
JP (1) JPS61500224A (enExample)
AU (1) AU583801B2 (enExample)
DE (1) DE3481172D1 (enExample)
WO (1) WO1985001871A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4815448A (en) * 1985-03-19 1989-03-28 Mills Randell L Mossbauer cancer therapy
US4815447A (en) * 1985-03-19 1989-03-28 Mills Randell L Mossbauer cancer therapy
JP2785025B2 (ja) 1985-03-19 1998-08-13 ランデル・エル・ミルズ 診断と選択的組織壊死を与える装置
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ES2273672T3 (es) * 1999-03-01 2007-05-16 Halogenetics, Inc. Uso de composiciones que comprenden cldc como radiosensibilizadores en el tratamiento de enfermedades neoplasticas.
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
EP2416781B1 (en) 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
UY32546A (es) 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
CS184526B1 (en) * 1976-02-19 1978-08-31 Dieter Cech 2'-halogen-2'-deoxy-5-fluoruridine,3',5-di-o-benzoyl-derivatives and process for preparing thereof
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases

Also Published As

Publication number Publication date
EP0160079A4 (en) 1986-05-14
WO1985001871A1 (en) 1985-05-09
DE3481172D1 (de) 1990-03-08
EP0160079B1 (en) 1990-01-31
JPS61500224A (ja) 1986-02-06
AU583801B2 (en) 1989-05-11
AU3610784A (en) 1985-05-22
EP0160079A1 (en) 1985-11-06

Similar Documents

Publication Publication Date Title
US4894364A (en) Method and materials for sensitizing neoplastic tissue to radiation
JP4117901B2 (ja) デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な方法
Gandhi et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)
US5719132A (en) Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
EP1491201B1 (en) Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides
AU583801B2 (en) Method and materials for sensitizing neoplastic tissue to radiation
Miller The metabolism and pharmacology of 5‐fluorouracil
US4434788A (en) Enhancer of anti-tumor effect
Grifantini Tiazofurine ICN pharmaceuticals
JPS637527B2 (enExample)
Huang et al. Effects of cytotoxicity of 2-chloro-2′-deoxyadenosine and 2-bromo-2′-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics
DE60030842T2 (de) VERWENDUNG VON ZUSAMMENSETZUNGEN ENTHALTEND CldC ALS STRAHLUNGSSENSIBILISATOREN IN DER BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN
NL8301913A (nl) Middel voor het versterken van de antitumor activiteit van een middel tegen tumoren.
US4432348A (en) Enhancer of anti-tumor effect
JPS637164B2 (enExample)
JP2688057B2 (ja) 抗腺がん剤
EP3563856B1 (en) Pharmaceutical composition comprising capecitabine, gimeracil, and oteracil for treating cancer and use thereof
HUP0302884A2 (hu) Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére
CA1269658A (en) Method and materials for sensitizing neoplastic tissue to radiation
Iigo et al. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice
EP1804816B1 (en) Combination therapy comprising cloretazine(tm)
US7157449B2 (en) Medicament for the treatment of diseases caused by parasitic protozoa
AU702469B2 (en) Composition and method of treating retroviral infection
Fujimoto et al. Hypothetical mechanism of therapeutic synergism induced by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride
Kritz et al. Pilot study of 5‐azacytidine (5‐AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia